FOLFOX versus FOLFIRI: A comparison of regimens in the treatment of colorectal cancer metastases

Anticancer Research

Volumn 25, Issue 1 B, 2005, Pages 563-576

  Pasetto, Lara Maria ^a   Jirillo, Antonio ^a   Iadicicco, Girolama ^a   Rossi, Elena ^a   Paris, Myriam Katja ^a   Monfardini, Silvio ^a  

^a UNIVERSITY HOSPITAL OF PADOVA   (Italy)

Author keywords

Chemotherapy; Colorectal cancer; Metastases; Review

Indexed keywords

FLUOROURACIL; FOLINIC ACID; HYDROXYUREA; IRINOTECAN; LEVAMISOLE; OXALIPLATIN;

ALOPECIA; CLINICAL TRIAL; COLON ADENOCARCINOMA; DEHYDRATION; DIARRHEA; DRUG COST; DRUG EFFICACY; DRUG HYPERSENSITIVITY; FATIGUE; FEBRILE NEUTROPENIA; GASTROINTESTINAL TOXICITY; HUMAN; INFECTION; ITALY; LEUKOPENIA; LIVER METASTASIS; MUCOSA INFLAMMATION; NAUSEA; NEUROTOXICITY; NEUTROPENIA; PARESTHESIA; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; SURVIVAL TIME; THROMBOCYTOPENIA; VOMITING;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; CLINICAL TRIALS; COLORECTAL NEOPLASMS; COST-BENEFIT ANALYSIS; FLUOROURACIL; HUMANS; LEUCOVORIN; LIVER NEOPLASMS; NEOPLASM METASTASIS; ORGANOPLATINUM COMPOUNDS; TIME FACTORS; TREATMENT OUTCOME;

EID: 16444372377     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (66)

1. Berinan RS, Portera CA and Ellis LM: Biology of liver metastases. Cancer Treat Rev 109: 183-206, 2001.
2. Malafosse R, Penna Ch, Sa Cunha A and Nordlinger B: Surgical management of hepatic metastasis from colorectal malignancies. Ann Oncol 12(7): 887-894, 2001.
3. Vogl TJ, Muller PK, Mack MG, Straub R, Engelmann K and Neuhaus P: Liver metastases: interventional therapeutic techniques and results, state of the art. Radiol 9(4): 675-684, 1999.
4. Jamison RL, Donohue JH, Nagorney DM et al: Hepatic resection for metastatic colorectal cancer results in current some patients. Arch Surg 132: 505-511, 1997.
5. Lorenz M, Muller H, Schramm H et al: Randomized trial of surgery versus surgery followed by adjuvant hepatic arterial infusion with 5-fluorouracil and folinic acid for liver metastases of colorectal cancer. Ann Surg 228: 756-764, 1998.
6. Langer B, Bleiberg H, Labianca R, Shepherd L et al: Fluorouracil (FU) plus 1-leucovorin (1-LV) versus observation after potentially curative resection of liver or lung metastases from colorectal cancer (CRC): results of the ENG (EORTC/NCIC CTG/G1VIO) randomized trial. Proc Am Soc Clin Oncol 21: 149 (abs 592), 2002.
7. Portier G, Rougier P, Milan C, Bouchè O et al: Adjuvant systemic chemotherapy (CT) using 5-fluorouracil and folinic acid after resection of liver metastases (LM) from colorectal cancer (CRC) origin. Proc Am Soc Clin Oncol 21: 133 (abs 528), 2002.
8. Hoff PM, Ansari R, Batist G, Cox J et al: Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study. J Clin Oncol 19(8): 2282-2292, 2001.
9. Shimada Y, Yoshino JM, Wakui A, Nakao I et al: Phase II study of CPT11, a new camptothecin derivative, in metastatic colorectal cancer. CPT11 Gastrointestinal Cancer Study Group. J Clin Oncol 11(5): 909-913, 1993.
10. Fuchs CS, Moore MR, Harker G, Villa L, Rinaldi D and Hecht JR: Phase III comparison of two irinotecan dosing regimens in second-line therapy of metastatic colorectal cancer. J Clin Oncol 21(5): 807-814, 2003.
11. Cunningham D, Pyrhonen S, James RD, Punt CJ et al: Randomized trial of CPT11 plus best supportive care alone after fluorouracil failure for patients with metastatic colorectal cancers. Lancet 552: 1413-1418, 1998.
12. Schmitt C, Blijham G, Jolain B, Rougier P and Van Cutsem E: Medical care consumption in a phase III trial comparing CPT11 with infusional 5-fluorouracil (5FU) in patients with metastatic colorectal cancer after 5FU failure. Anticancer Drugs 10(6): 617-623, 1999.
13. Rougier P, Van Cutsem E, Bajetta E et al: Randomized trial of CPT11 versus fluorouracil continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer. Lancet 352: 1407-1412, 1998.
14. Shimada Y, Rougier P and Pitot H: Efficacy of CPT11 (irinotecan) as a single agent in metastatic colorectal cancer. Eur J Cancer 32(suppl 3): 13-17, 1996.
15. Firvida JL, Irigoyen A, Vazquez-Estevez S, Diz P, Constenia M, Casal-Rubio J et al: Phase II study of CPT11 as first-line chemotherapy for patients with advanced colorectal carcinoma. Cancer 91(4): 704-711, 2001.
16. Andre T, Louvet C, Maindrault-Goebel F, Couteau C et al: CPT11 (irinotecan) addition to bimonthly, high dose leucovorin and bolus and continuous infusion 5-fluorouracil ("folfiri") for pretreated metastatic colorectal cancer. GERCOR. Eur J Cancer 35(9): 1343-1347, 1999.
17. Douillard JY: CPT11 and high dose fluorouracil/leucovorin for metastatic colorectal cancer. Oncology 14(12 suppl14): 51-55, 2000.
18. Mabro M, Louvet C, Andre T, Carola E et al: Bimonthly leucovorin, infusion 5-fluorouracil, hydroxyurea, and irinotecan ("folfiri"-2) for pretreated metastatic colorectal cancer. Am J Clin Oncol 26(3): 254-258, 2003.
19. Maindrault-Goebel F, Louvet C, Carola C and de Gramont A: Leucovorin, 5-fluorouracil infusion and CPT11 ("folfiri"-3) in pretreated patients with metastatic colorectal cancer. Proc Am Soc Clin Oncol 21: 165 (abs 658), 2002.
20. Mabro M, Artru M, Flesch M, Maindrault-Goebel F et al: Irinotecan, 5-fluorouracil infusion and leucovorin, ("folfiri"-3) in pretreated patients with metastatic colorectal cancer: results of a multicenter phase II study. Proc Am Soc Clin Oncol 22: 280 (abs 1125), 2003.
21. Garufi C, Dogliotti L, D'Attino RM et al: Irinotecan and chronomodulated infusion of 5-fluorouracil and folinic acid in the treatment of patients with advanced colorectal carcinoma: a phase I study. Cancer 15; 91(4): 712-720, 2001.
22. Vamvakas L, Kakolyris S, Kououssis C, Kandilis K et al: Irinotecan (CPT11) in combination with infusional 5-fluorouracil and leucovorin (de Gramont regimen) as I line treatment in patients with advanced colorectal cancer: a multicenter phase II study. Am J Clin Oncol 25(7): 65-70, 2002.
23. Van Cutsem E, Pozzo C, Starkhammar H, Dirix L et al: A phase II study of CPT11 alternated with five days bolus of 5-fluorouracil and leucovorin in first-line chemotherapy of metastatic colorectal cancer. Ann Oncol 9(11): 1199-1204, 1998.
24. Saltz LB, Cox JV, Blanke C et al: CPT11 plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med 343: 905-914, 2000.
25. Douillard JY, Cunnigham D, Roth AD, Navarro M et al: CPT11 combined with fluorouracil compared with fluorouracil alone as I line treatment for metastatic colorectal cancer: a multicenter randomized trial. Lancet 355: 1041-1047, 2000.
26. Pozzo C, Basso M, Massidda B et al: A randomized phase III multicenter trial comparing irinotecan CPT11 alternating with bolus 5-fluorouracil + folinic acid to bolus 5-fluorouracil + folinic acid (Mayo Clinic) in I line treatment of metastatic colorectal cancer. Proc Am Soc Clin Oncol 21: 100 (abs 2213), 2002.
27. Maindrault-Goebel F, Louvet C, André T et al: Time to disease control (TDC) to evaluate the impact on survival of three chemotherapy lines in metastatic colorectal cancer (MRC) based on 5-fluorouracil, oxaliplatin and irinotecan (GERCOR). Proc Am Soc Clin Oncol 19: 146 (581), 2001.
28. Glimelius B, Ristamaki R, Kyaer M et al: Irinotecan combined with bolus 5-fluorouracil and folinic acid Nordic schedule as I line therapy in advanced colorectal cancer. Ann Oncol 13: 1868-1873, 2002.
29. Becouarn Y, Ychou M, Ducreux M et al: Phase II trial of oxaliplatin as first-line chemotherapy in metastatic colorectal cancer patients. Digestive Group of French Federation of Cancer Centers. J Clin Oncol 16(8): 2739-2744, 1998.
30. Cassidy J: Review of oxaliplatin: an active platinum agent in colorectal cancer. Int J Clin Pract 54(6): 399-402, 2000.
31. de Gramont A, Tournigand C, Louvet C, Andre T et al: Oxaliplatin, folinic acid and 5-fluorouracil ("folfox") in pretreated patients with metastatic advanced cancer. The GERCOD. Rev Med Intern 18(10): 769-775, 1997.
32. de Gramont A, Vignoud J, Tournigand C et al: Oxaliplatin with high dose leucovorin and 5-fluorouracil 48-hour continuous infusion in pretreated metastatic colorectal cancer. Eur J Cancer 33: 214-219, 1997.
33. Andre T, Louvet C, Raymond E, Tournigand C and de Gramont A: Bimonthly high dose leucovorin, 5-fluorouracil infusion and oxaliplatin ("folfox" 3) for metastatic colorectal cancer resistant to the same leucovorin and 5-fluorouracil regimen. Ann Oncol 9(11): 1251-1253, 1998.
34. Andre T, Bensamine MA, Louvet C, Francois E et al: Multicenter phase II study of bimonthly high dose leucovorin, fluorouracil infusion and oxaliplatin for metastatic colorectal cancer resistant to the same leucovorin and 5-fluorouracil regimen. J Clin Oncol 17(11): 3560-3568, 1999.
35. Maindrault-Goebel F, Louvet C, Andre T, Carola E et al: Oxaliplatin added to the simplified bimonthly leucovorin and 5-fluorouracil regimen as second-line therapy for metastatic colorectal cancer (FOLFOX6). GERCOR. Eur J Cancer 35(9): 1338-1342, 1999.
36. Maindrault-Goebel F, de Gramont A, Louvet C, Andre T et al: Evaluation of oxaliplatin dose intensity in bimonthly leucovorin and 48-hour 5FU continuous infusion regimen ("folfox") in pretreated metastatic colorectal cancer. Oncology Multidisciplinary Research Group (GERCOR). Ann Oncol 11(11): 1477-1483, 2000.
37. Mosconi S, Cascinu S, Zaniboni A, Catalano V et al: The value of oxaliplatin in combination with continuous infusion ± bolus 5FU and levo-folinic acid in metastatic colorectal progressing after 5FU-based chemotherapy: a GISCAD (Italian Group for the Study of Digestive Tract). Tumori 86(6): 465-469, 2000.
38. Maindraudt-Goebel F, de Gramont A, Louvet C, Andre T et al: High-dose intensity oxaliplatin added to the simplified bimonthly leucovorin and 5-fluorouracil regimen as second-line therapy for metastatic colorectal cancer (FOLFOX 7). Eur J Cancer 37(8): 1000-1005, 2001.
39. Andre T, Figer A, Cervantes A, Lledo G et al: "Folfox" 7 compared to "folfox" 4. Preliminary results of the randomized optimox study. Proc Am Soc Clin Oncol 22: 253 (abs 1016), 2003.
40. Chau I, Webb A, Norman A, Massey A, Hill M and Cunningham D: A phase II study of protracted venous infusion 5-fluorouracii and oxaliplatin in patients with advanced or relapsed, 5FU pretreated colorectal cancer. Proc Am Soc Clin Oncol 20: 140 (abs 557), 2001.
41. Rothenberg M, Oza A, Burger B et al: Phase III trial of bolus + infusional 5FU/leucovorin versus oxaliplatin versus the combination in patients with recurrent metastatic colorectal cancer following irinotecan, bolus 5FU and leucovorin: interim results. Presented at the 27th European Society for Medical Oncology. Nice, France, October 18-22, 2002.
42. Levi F, Zidani R, Misset JL et al: Randomized multicenter chronotherapy with oxaliplatin, fluorouracil and folinic acid in metastatic colorectal cancer. Lancet 550: 681-686, 1997.
43. Giacchetti S, Perpoint B, Zidani R et al: Phase III multicenter trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as I line treatment of metastatic colorectal cancer. J Clin Oncol 18: 136-147, 2000.
44. Levi F, Zidani R, Brienza S et al: A multicenter phase II trial of intensified chronotherapy with oxaliplatin (1-OHP), 5-fluorouracil (5-FU) and folinic acid (LV) in patients (PTS) with previously untreated metastatic colorectal cancer (MMC). Cancer 85: 2532-2540, 1999.
45. Giacchetti S, Itzahaki M, Gruia G, Adam R et al: Long term survival of patients with unresectable colorectal cancer liver metastases following infusional chemotherapy with 5-fluorouracil, leucovorin, oxaliplatin and surgery. Ann Oncol 10(6): 663-669, 1999.
46. Giacchetti S, Bjarnason GA, Garufi C, Canon N et al: First-line infusion of 5-fluorouracil, leucovorin, oxaliplatin for metastatic colorectal cancer chronomodulated versus conventional delivery, a multicenter randomized trial of the EORTC chronotherapy group. Proc Am Soc Clin Oncol 21: 104 (abs 2231), 2002.
47. de Gramont A, Figer A, Seymour M et al: Leucovorin and fluorouracil with or without oxaliplatin as first-line therapy for metastatic colorectal cancer. J Clin Oncol 18: 2938-2947, 2000.
48. Kouroussis C, Souglakos J, Kakolyris S, Mavroudis D et al: Oxaliplatin in combination with infusional 5-fluorouracil and leucovorin every 2 weeks as I line treatment in patients with advanced colorectal cancer: a phase II study. Oncology 61(1): 36-41, 2001.
49. Grothey A, Descler B, Kroening H et al: Bolus 5-fluorouracil/folinic acid (Mayo) versus weekly high dose 24 H 5FU infusion/FA + oxaliplatin in advanced colorectal cancer. Results of a phase III study. Proc Am Soc Clin Oncol 20: 125 (abs 496), 2001.
50. Hochster HS, Chachoua A, Speyer J et al: First-line activity of oxaliplatin with weekly bolus 5FU and low-dose leucovorin (LV) in advanced colorectal cancer (CRC). Proc Am Soc Clin Oncol 20: 138 (abs 548), 2001.
51. Tournigand C, Andrè T, Achille E, Lledo G et al: "Folfiri" followed by "folfox 6" or the reverse sequence in advanced colorectal cancer: a randomised GERCOR study. J Clin Oncol 22(2): 229-237, 2004.
52. Morton RF, Golberg RM, Sargent DJ, Fuchs CS and O'Connell MJ: Oxaliplatin or CPT11 combined with 5FU/leucovorin in advanced colorectal cancer: an NCCTG/CALBG study. Proc Am Soc Clin Oncol 20: 125 (abs 495), 2001.
53. Rothenberg ML, Meropol MJ, Poplin EA, Van Cutsem E and Wadler S: Mortality associated with irinotecan plus bolus fluorouracil/leucovorin: summary findings of an independent panel. J Clin Oncol 19: 3801-3807, 2001.
54. Goldberg RM, Morton RF, Sargent DJ, Fuchs CS et al: Oxaliplatin or CPT11 + 5-fluorouracil (5FU)/leucovorin (LV) or oxaliplatin + CPT11 in advanced colorectal cancer (CRC). Initial toxicity and response data from a GI Intergroup Study. Proc Am Soc Clin Oncol 21: 128 (abs 511), 2002.
55. Goldberg RM, Sargent DJ, Morton RF, Fuchs CS et al: A randomised controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 22(1): 23-30, 2004.
56. Schalhorn A, Stauch M, Quietzsch D, Maubach P et al: CPT11 plus oxaliplatin versus CPT11 plus 5FU/folinic acid (FA) as I line treatment in metastatic colorectal cancer (CRC): interim toxicity analysis of a randomized phase III trial. Proc Am Soc Clin Oncol 21: 149 (abs 594), 2002.
57. Souglakos J, Athanasiadis A, Ginopoulos P, Giannakakis T et al: Oxaliplatin (L-OHP) combined with CPT11 (CPT11), leucovorin (LV) and 5-fluorouracil (5FU) ("folfox"IRI) compared with CPT11, LV, and 5FU ("folfiri") as I line treatment for metastatic colorectal cancer: preliminary safety and efficacy results of a multicenter randomized trial. Proc Am Soc Clin Oncol 21: 153 (abs 608), 2002.
58. Comella P, Buzzi F, Iannelli A, Mancarela S et al: Oxaliplatin plus leucovorin/fluorouracil i.v. bolus (OXAFAFU) versus CPT11 plus leucovorin/fluorouracil i.v. bolus (IRIFAFU) as I line treatment of advanced colorectal carcinoma (ACC): SICOG 0103 randomised study. Proc Am Soc Clin Oncol 21: 162 (abs 645), 2002.
59. Falcone A, Masi G, Brunetti I et al: "FolfoxIRI" versus "folfiri" as first-line treatment in metastatic colorectal cancer patients: preliminary safety results of a randomised phase III trial of the Gruppo Oncologico Nord Ovest (GONO). Proc Am Soc Clin Oncol 22: 346 (abstr 1388), 2003.
60. Salgado M, Grande C, Ramos M et al: A multicenter prospective non-randomized trial of irinotecan, 5-fluorouracil and leucovorin versus oxaliplatin, 5FU and LV in patients with untreated metastatic colorectal carcinoma: preliminary results. Proc Am Soc Clin Oncol 22: 354 (abstr 1421), 2003.
61. Cascinu S, Graziano F, Ferrau F, Catalano V et al: Raltitrexed plus oxaliplatin (TOMOX) as I line chemotherapy for metastatic colorectal cancer. A phase II study of the Italian Group for the Study of Gastrointestinal Tract Carcinomas (GISCAD). Ann Oncol 13(5): 716-720, 2002.
62. Martoni A, Mini E, Pinto C, Gentile AL et al: Oxaliplatin plus raltitrexed in the treatment of patients with advanced colorectal cancer: a phase II study. Anticancer Res 23(1B): 687-691, 2003.
63. Pasetto LM, Rossi E and Monfardini S: Liver metastases of colorectal cancer: medical treatments. Anticancer Res 23(5b): 4245-4256, 2003.
64. Recchia F, Nuzzo A, Lalli A, Di Lullo L et al: Multicenter phase II study of CPT-11 fractionated over two days with bimonthly leucovorin and 5-fluorouracil in patients with metastatic colorectal cancer. Anticancer Res 23(3C): 2903-2908, 2003.
65. Guthoff I, Lotspeich E, Fester C, Wallin I, Schatz M, Ehrsson H and Kornmann M: Hepatic artery infusion using oxaliplatin in combination with 5-fluorouracil, folinic acid and mitomycin C: oxaliplatin pharmacokinetics and feasibility. Anticancer Res 23(6D): 5203-5208, 2003.
66. Mancuso A, Giuliani R, Accettura C, Palma M et al: Hepatic arterial continuous infusion (HACI) of oxaliplatin in patients with unresectable liver metastases from colorectal cancer. Anticancer Res 23(2C): 1917-1922, 2003.